Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
3,291 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Exercise, physical activity, and physical fitness in psoriasis and psoriatic arthritis: an umbrella review
Lyu Z, Ma J, Ma C, Tian X, Liu L, Zhang J, Gao Y. · Front Immunol · cited 0 timesOpen accesssystematic-review, review
- Epidemiology of Diabetes Mellitus in Patients With Psoriatic Arthritis: Current Evidence.
Wang J, Zhou X, Chen J, Wang Q, Yi X, Gao P, He J, Yang S, Zhang M, Sun X, Liu L, Li X. · Diabetes Metab Res Rev · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Efficacy and safety evaluation of adalimumab for psoriatic arthritis: A meta-analysis.
Cai Z, Yan L, Zhang Y. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessmeta-analysis
- Exercise, physical activity, and physical fitness in psoriasis and psoriatic arthritis: an umbrella review.
Lyu Z, Ma J, Ma C, Tian X, Liu L, Zhang J, Gao Y. · Front Immunol · 2026 · cited 0 timesresearch support, non-u.s. gov't, systematic review
- Effect of Bimekizumab Treatment on Health Status, Work Productivity, and Productivity Costs Through 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis.
Nikiphorou E, Tillett W, Deodhar A, Dubreuil M, Gossec L, Hwang M, Lubrano E, Machado PM, Rudwaleit M, de Wit M, Kavanagh S, de la Loge C, Ink B, Healy P, Lambert J, Mørup M, Boonen A, Walsh J. · J Rheumatol · 2026 · cited 0 timesclinical trial, phase iii, randomized controlled trial
- Biologic therapies and psoriatic arthritis risk in psoriasis: A systematic review and meta-analysis.
Yang L, Gao X, Wang Z, Wu D. · J Eur Acad Dermatol Venereol · 2026 · cited 0 timesmeta-analysis, systematic review
- Prevalence and clinical relevance of anti-drug antibodies in psoriatic arthritis: a systematic review.
Kimpton J, Akpabio A, Watts A, Tansley S, Smith T, McHugh N, Tillett W. · RMD Open · 2026 · cited 0 timesOpen accesssystematic review
- Prognostic prediction models for psoriatic arthritis in psoriasis: A systematic review.
Khoda F, Khan Y, Haw WWY, Nahar S, Hodkinson C, Chinoy H, Warren RB, Martin GP, Yiu ZZN. · J Eur Acad Dermatol Venereol · 2026 · cited 3 timesOpen accesssystematic review, review-article
- Impact of Biologic Therapies on the Risk of Progression from Psoriasis to Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies.
Xie W, Chen T, Chen Y, Xiao S. · Am J Clin Dermatol · 2026 · cited 0 timesmeta-analysis, systematic review
- Efficacy, Safety, and Tolerability of Secukinumab in Psoriatic Arthritis: A Systematic Review and Meta-Analysis.
Khan MS, Khan SM, Farooq R, Arif A, Murshid A, Abdullah M, Ismail A, Hussain JM, Rahim S, Ahmed SN, Khan SRM. · Ann Pharmacother · 2026 · cited 0 timesmeta-analysis, systematic review
- Cost-Utility Analyses of Systemic Treatments for Psoriasis and Psoriatic Arthritis in the UK: A Systematic Review of Modelling Methods.
Clemmet TS, Phan DB, Copson A, Warren RB, Yiu ZZN, Rogers G. · Pharmacoeconomics · 2026 · cited 0 timessystematic review
- Prevalence of interstitial lung disease in patients with psoriatic arthritis: a systematic review and meta-analysis.
Nakaphan P, Shotelersuk V, Pajareya P, Siranart N, Ifteqar S. · Clin Rheumatol · 2026 · cited 0 timesmeta-analysis, systematic review
- IL-17 ligand-targeting inhibitors in psoriatic arthritis: a focused systematic review and network meta-analysis of efficacy, safety, and certainty of evidence.
AbuJwaid YK, Assi AK, Amro AM, Awwad HH, Ehmidat M, Deeb S, Awlad Mohammad MW, Dwayat A, Odeh A, Albow Y, Yasini M, Alfrookh M, Alamlih L. · Front Immunol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Extrapolating Guselkumab Efficacy to Juvenile Psoriatic Arthritis from Adult Psoriatic Arthritis and Adult and Pediatric Psoriasis Data.
Crauwels H, Ringold S, Howard S, Van Hartingsveldt B, Smith V, Jett M, Baguet T, Adamson E, Chakravarty SD, Leu JH. · Paediatr Drugs · 2026 · cited 4 timesOpen accessrandomized controlled trial
- Efficacy and safety of upadacitinib in patients with psoriatic arthritis and exposure to one anti-TNF: post hoc analysis of SELECT-PsA 2.
Coates LC, Mease P, Kavanaugh A, Merola JF, Magrey M, Iyile T, Zhou L, Novelli L, Lagunes I, Setty AR, Van den Bosch F. · RMD Open · 2026 · cited 0 timesOpen accessmulticenter study, randomized controlled trial
- Predicting clinical response in psoriatic arthritis through integrative analysis of transcriptomics and proteomics.
Bentvelzen MLM, El Bouhaddani S, Spierings J, Concepcion AN, Vonkeman HE, Mooij SC, Schipper LG, Herman A, Vreugdenhil SA, TOFA-PREDICT author group, Mastbergen SC, Welsing PMJ. · Arthritis Res Ther · 2026 · cited 0 timesOpen accessrandomized controlled trial
- Effects of biologics and small-molecule inhibitors on lipid profiles in patients with psoriasis or psoriatic arthritis: An analysis of current evidence.
Zhang M, Gao P, Li Y, Cao R, Zhou X, Liu L, Wu H, Wang J, Cai X, Hong S, Sun X, Su Y, Li X. · Autoimmun Rev · 2026 · cited 0 timesmeta-analysis, systematic review
- Circulating immune cell biomarkers in Psoriatic Arthritis: associations with clinical manifestations and treatment response in the TOFA-PREDICT trial.
Perton FT, Pouw JN, Spierings J, Kors DN, Concepcion AN, Bekker CPJ, Vonkeman HE, Mooij SC, Schipper LG, Herman A, Vreugdenhil SA, TOFA-PREDICT author group, Mastbergen SC, Welsing PMJ. · Arthritis Res Ther · 2026 · cited 0 timesOpen accessrandomized controlled trial
- Effect of apremilast on whole-body magnetic resonance imaging of peripheral and axial inflammation in patients with psoriatic arthritis.
Østergaard M, Lambert RGW, Maksymowych WP, Boesen M, Bubb MR, Kubassova O, Valenzuela G, Colgan S, Deignan C, Zhou Z, Mease PJ. · Ann Rheum Dis · 2026 · cited 0 timesmulticenter study, clinical trial, phase iv
- Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOST.
Coates LC, Gladman DD, Merola JF, Mrowietz U, Armstrong A, Baraliakos X, Tillett W, Kishimoto M, Reddy J, Teng L, Amouzadeh H, Deignan C, Mease PJ, Gossec L. · Rheumatology (Oxford) · 2026 · cited 0 timesOpen accessresearch support, non-u.s. gov't, multicenter study
- Cycling versus swapping strategies for treatment of psoriatic arthritis after primary tumour necrosis factor inhibitors failure: a systematic review and meta-analysis.
Tomo ATJ, Ratan P, Gonçalves LS, Marques TC, Souza MEC, Finn LC, Rima JAA, Moreira GSF. · Rheumatology (Oxford) · 2026 · cited 1 timesmeta-analysis, systematic review
- Differences in clinical features between axial psoriatic arthritis and axial spondyloarthritis: a systematic review and meta-analysis of observational studies.
Qiu Z, Chen Z, Yang Z, Xia R, Chen W, Zhu Y, Wang W, Li Z, Yang K. · Front Med (Lausanne) · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis.
Annfeldt TK, Händel MN, Haugegaard T, Henriksen M, Coates LC, Ogdie A, Tillett W, Goel N, Gladman DD, Orbai AM, de Wit M, Strand V, Mease PJ, FitzGerald O, Helliwell PS, Tugwell P, Leung YY, Christensen R. · Ann Rheum Dis · 2026 · cited 2 timessystematic review, network meta-analysis
- Efficacy and safety of golimumab biosimilar BAT2506 in patients with active psoriatic arthritis after switching from reference golimumab: 52-week results of a phase 3, double-blind, randomized study.
Tang H, Dokoupilova E, Batko B, Zawadzki M, Batalov A, Liu Y, Yang X, Zhou Y, Dong Q, Liu Y. · Expert Opin Biol Ther · 2026 · cited 0 timesclinical trial, phase iii, multicenter study
- Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies.
Gossec L, Coates LC, Landewé RBM, Mease PJ, Merola JF, Ritchlin CT, Tanaka Y, Asahina A, Proft F, Goldammer N, Manente M, Ink B, Bajracharya R, Coarse J, McInnes IB. · Rheumatology (Oxford) · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.